The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed ...

Treatment with an Enhertu regimen significantly improved pathologic complete responses for patients with high-risk ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...

First Phase III trial to demonstrate benefit of ENHERTU in early breast cancer WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the DESTINY-Breast11 Phase III trial showed ...

Topline results from the Phase III DESTINY-Breast11 trial show that Enhertu (trastuzumab deruxtecan) followed by paclitaxel, ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...

AstraZeneca (LSE:AZN) recently experienced positive developments, including the European approval of Calquence for mantle ...

Greenwich LifeSciences showed initial HER2 data, yet faces funding issues and competitive pressure in a fast-moving field. See why GLSI stock is a sell.

The trial aims to assess the neoadjuvant Enhertu single agent or Enhertu followed by THP versus the standard of care regimen in individuals with HER2-positive early-stage breast cancer.